RecruitingPhase 1 / Phase 2NCT06239272
Rare condition
Epithelioid hemangioma
5
studies recruiting now
as of 7 Sept 2026
18
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
5 Aug 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07104331
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
RecruitingNCT06408441
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
RecruitingNot applicableNCT03967834
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
RecruitingPhase 1NCT06452160
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Epithelioid hemangioma studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Epithelioid hemangioma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Epithelioid hemangioma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (FOSB, ZFP36L2, LMNA, VIM, FOS).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).